Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Insider Sells $295,812.50 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Lance Baldo sold 6,250 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $47.33, for a total value of $295,812.50. Following the completion of the sale, the insider now owns 6,250 shares of the company’s stock, valued at $295,812.50. The transaction was disclosed in a filing with the SEC, which is available through this link.

Lance Baldo also recently made the following trade(s):

  • On Tuesday, June 9th, Lance Baldo sold 6,250 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $43.73, for a total value of $273,312.50.
  • On Wednesday, May 6th, Lance Baldo sold 50,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $33.86, for a total value of $1,693,000.00.

Adaptive Biotechnologies stock opened at $48.54 on Friday. Adaptive Biotechnologies Corporation has a 1 year low of $15.19 and a 1 year high of $55.12. The firm’s 50 day moving average price is $43.22 and its 200-day moving average price is $32.74.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.04). The company had revenue of $20.91 million for the quarter, compared to analysts’ expectations of $21.52 million. Adaptive Biotechnologies had a negative net margin of 87.47% and a negative return on equity of 22.92%. The firm’s revenue for the quarter was up 65.1% compared to the same quarter last year. As a group, analysts anticipate that Adaptive Biotechnologies Corporation will post -1.06 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Adaptive Biotechnologies in the first quarter worth about $27,000. American International Group Inc. increased its stake in Adaptive Biotechnologies by 300.0% in the 1st quarter. American International Group Inc. now owns 1,392 shares of the company’s stock worth $39,000 after acquiring an additional 1,044 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in Adaptive Biotechnologies by 104.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,614 shares of the company’s stock worth $45,000 after acquiring an additional 825 shares during the last quarter. Rockefeller Capital Management L.P. raised its holdings in shares of Adaptive Biotechnologies by 548.6% during the 1st quarter. Rockefeller Capital Management L.P. now owns 3,840 shares of the company’s stock worth $107,000 after acquiring an additional 3,248 shares in the last quarter. Finally, First Mercantile Trust Co. boosted its position in shares of Adaptive Biotechnologies by 66.7% during the 1st quarter. First Mercantile Trust Co. now owns 4,000 shares of the company’s stock valued at $111,000 after acquiring an additional 1,600 shares during the last quarter. Hedge funds and other institutional investors own 76.23% of the company’s stock.

A number of research analysts have recently weighed in on ADPT shares. Goldman Sachs Group began coverage on Adaptive Biotechnologies in a research report on Wednesday, June 3rd. They set a “buy” rating and a $60.00 price objective on the stock. ValuEngine downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd. Zacks Investment Research lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Monday, May 11th. BTIG Research restated a “buy” rating and set a $46.00 price objective on shares of Adaptive Biotechnologies in a research report on Friday, April 17th. Finally, Guggenheim upped their target price on shares of Adaptive Biotechnologies from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, May 19th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Adaptive Biotechnologies currently has a consensus rating of “Buy” and an average price target of $47.67.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals.

Recommended Story: Purposes and Functions of the Federal Reserve

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.